Studies have confirmed that a unique method of "Trojan horse", recently introduced in the struggle with some preparative types of cancer, is able to induce a truly positive reaction even in the bad cancer cases.
"Trojan horse": what is it?
"Trojan horse" for the action particularly doctors call the newest drug to get a unique name Tizotumab-vedotin (tisotumab vedotin, TV), which enters the body onco-patient releases deep toxic substance which destroys the malignant cells inside. Currently, inspired by positive experimental results, scientists have already moved to the second phase of clinical trials of this unique tool.
Thus, the new preparation acts like a Trojan horse, unexpectedly penetrating the cell neoplasms. In the process of experimental trials in patients with various types of cancer medicine showed promising results immediately to the six tumor types. In particular, sensitive to the original drug proved to be more than a quarter of surveyed patients suffering from malignant cervical and bladder tumors in advanced conditions, as well as 15% - with ovarian cancer and oncology lungs.
Clinical researches
Specialists of the Institute of Cancer Research (London, UK), together with colleagues working in the Fund Royal Marsden NHS Foundation carried out a series of clinical trials (First / second binding phase) among the one hundred and fifty patients suffering from various cancers and fail to respond to standard designee for their disease treatment. During the experiments it was found: a considerable amount of subjects susceptible to the test drug. Their tumors were reduced in size and / or stop growing.
During the tests there was a positive response in 27% of patients suffering from bladder cancer, in 26.5% - with cancer cervix uterus, 14% - with ovarian tumors, 13% - with esophageal cancer and non-small cell lung cancer, 7% - with malignancies Endometrial. Changes occurred, on average, about six months, and in some patients have lasted up to 10 months.
Among the side effects of drug action in the subjects were noted: epistaxis, fatigue, nausea, vision problems.
Read more about the drug
The structure of the new drug enters toxic substance "attached" to the tail antibody, seeker receptor in the body (so called "tissue factor"), which many cancer cells on the shell (namely it leads to lower threshold survival). By binding to tissue factor, drug constituting drug spends in the tumor to destroy it inside the cell.
The TV is currently involved in research on cancer of other organs, including the intestines, pancreas, brain and neck. He is also involved in the testing of the second phase of the second-line therapeutic diagnosed with cervical cancer.
Want to know more about medicine? Do not forget to support our channel in service Yandex. Zen Like and subscription. It motivates us to publish more interesting materials. Also, you can quickly learn about new publications.
